N
IPSC icon

Nuveen’s Century Therapeutics IPSC Stock Holding History

Nuveen’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-157,311
Closed -$74.9K – 3329
2025
Q1 		$74.9K Hold
157,311
– – ﹤0.01% 3241
2024
Q4 		$159K Buy
157,311
+51,661
+49% +$70.3K ﹤0.01% 3244
2024
Q3 		$181K Hold
105,650
– – ﹤0.01% 3242
2024
Q2 		$269K Buy
105,650
+45,611
+76% +$144K ﹤0.01% 3172
2024
Q1 		$251K Hold
60,039
– – ﹤0.01% 3134
2023
Q4 		$199K Buy
60,039
+1,087
+2% +$1.98K ﹤0.01% 3217
2023
Q3 		$118K Hold
58,952
– – ﹤0.01% 3111
2023
Q2 		$186K Hold
58,952
– – ﹤0.01% 3104
2023
Q1 		$205K Sell
58,952
-1,087
-2% -$4.77K ﹤0.01% 2986
2022
Q4 		$308K Sell
60,039
-15,742
-21% -$149K ﹤0.01% 2981
2022
Q3 		$750K Buy
75,781
+26
+0% +$274 ﹤0.01% 2850
2022
Q2 		$636K Buy
75,755
+50,765
+203% +$498K ﹤0.01% 2955
2022
Q1 		$290K Buy
24,990
+8,289
+50% +$110K ﹤0.01% 3129
2021
Q4 		$223K Hold
16,701
– – ﹤0.01% 3224
2021
Q3 		$420K Buy
+16,701
New +$452K ﹤0.01% 3201

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's IPSC Position: Q2 2025 in Review

Nuveen sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 157,311 shares — an estimated $74.9K sold.

Nuveen first reported a position in IPSC in Q3 2021 and held it in 15 quarters. The position peaked at $750K in Q3 2022. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • Nuveen reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 157,311 Century Therapeutics shares in Q2 2025, an estimated $74.9K.
  • Nuveen first reported a position in Century Therapeutics in Q3 2021 and held it in 15 quarters.
  • Nuveen's Century Therapeutics position peaked at $750K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.